Introduction B cells are implicated in MS pathophysiology. Ocrelizumab (OCR) is a humanised monoclonal antibody that selectively targets CD20+ B cells. OCR was evaluated in relapsing MS (RMS) in two identical, Phase III, randomised, double-blind, double-dummy, interferon beta-1a (IFNβ-1a)-controlled studies (OPERA I/NCT01247324 and OPERA II/NCT01412333).
Methods Eligible RMS patients were randomised 1:1 to receive OCR 600 mg every 24 weeks or IFNβ-1a 44 µg three-times weekly for 96 weeks. The primary endpoint was annualised relapse rate (ARR) by 96 weeks. Key secondary endpoints included: time to 12- and 24-week confirmed disability progression (CDP); total number of T1 gadolinium-enhancing and new/enlarging T2 lesions at weeks 24, 48 and 96; and safety.
Results Compared with IFNβ-1a, OCR reduced: ARR (OPERA I: 46%; OPERA II: 47%; both p<0.0001); 12- and 24-week CDP by 40% each (p=0.0006; p=0.0025, respectively) in pre-specified pooled analyses; T1 gadolinium-enhancing lesions (OPERA I: 94%; OPERA II: 95%; both p<0.0001); and new/enlarging T2 lesions (OPERA I: 77%; OPERA II: 83%; both p<0.0001). Except for infusion- and injection-related events, adverse events (AEs) and serious AEs were similar between groups.
Conclusions OCR demonstrated significantly superior efficacy vs IFNβ-1a and a favourable safety profile in RMS patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.